Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 4, 2023

Serological Testing versus 3.0T Magnetic Resonance IDEAL and IDEAL IQ Technology for Quantitative Evaluation of Fatty Liver

Download as PDF

DOI: 10.23977/medsc.2023.040410 | Downloads: 10 | Views: 377

Author(s)

Liangliang Pan 1, Huafang Guan 1, Xiaoyong Wu 1, Jiman Shao 1

Affiliation(s)

1 Department of Radiology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, 330006, China

Corresponding Author

Jiman Shao

ABSTRACT

Fatty liver is a prevalent chronic liver disease with an increasing incidence and severity that can result in severe consequences such as hepatitis, cirrhosis, and liver cancer. This study aims to investigate the pathogenesis and early diagnostic methods for fatty liver by selecting a healthy control group and a fatty liver group. The differences in three serological indicators (TG, TC, and HDL-C values) and liver fat content values (fat content and relaxation rate image R2*) measured by magnetic resonance IDEAL and IDEAL IQ technology were detected between the two groups. The results showed that the fatty liver group had abnormal serological indicators, with significantly increased liver fat content values and R2* values. These values were positively correlated with serum TG and TC values and negatively correlated with serum HDL-C values. These findings suggest that serological indicators and magnetic resonance imaging technology can serve as effective means of assessing the degree and risk of fatty liver, providing a basis for its prevention and treatment.

KEYWORDS

Efficacy, IQ Technology, Serological Testing, Fatty Liver

CITE THIS PAPER

Liangliang Pan, Huafang Guan, Xiaoyong Wu, Jiman Shao, Serological Testing versus 3.0T Magnetic Resonance IDEAL and IDEAL IQ Technology for Quantitative Evaluation of Fatty Liver. MEDS Clinical Medicine (2023) Vol. 4: 66-71. DOI: http://dx.doi.org/10.23977/medsc.2023.040410.

REFERENCES

[1] Polidoro MA, Ferrari E, Marzorati S, Lleo A, Rasponi M (2021). Experimental liver models: From cell culture techniques to microfluidic organs-on-chip (in English). Liver Int Aug; 41(8): 1744-1761.
[2] Feldstein AE, Canbay A, Angulo P, et al (2003). Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis (in English). Gastroenterology Aug; 125(2): 437-443.
[3] Eshraghian A, Hamidian Jahromi A (2014). Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review (in English). World J Gastroenterol Jun 28; 20(25): 8102-8109.
[4] Chalasani N, Younossi Z, Lavine JE, et al (2018). The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases (in English). Hepatology Jan; 67(1): 328-357.
[5] Yao CJ, Wang YH, Zhang YL, et al (2012). Research progress of external therapies of traditional Chinese medicine in the treatment of non-alcoholic fatty liver disease (in Chinese). J Hainan Med Univ Dec; 28(6): 5-8.
[6] Kumar CVC, Skantha R, Chan WK (2021). Non-invasive assessment of metabolic dysfunction-associated fatty liver disease (in English). Ther Adv Endocrinol Metab Jul; 13: 20420188221139614.
[7] Kim HJ, Kim HJ, Lee KE, et al (2014). Alcoholic fatty liver disease elevates estimated coronary heart disease risk to levels comparable with those of nonalcoholic fatty liver disease in the Korean population: a cross-sectional study (in English). Clin Mol Hepatol Jun; 20(2): 182-189.
[8] Seen TK, Kim YJ, Park SH, et al (2021). Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis (in English). World J Gastroenterol Jun 21; 27(23): 3238-3248.
[9] Enjoji M, Yasutake K, Kohjima M, Nakamuta M (2014). Nutrition and nonalcoholic fatty liver disease: The significance of cholesterol (in English). World J Gastroenterol Jul 14; 20(27): 8920-8929.
[10] Lee YH, Kim SU, Song K, et al (2016). Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study (in English). Liver Int Apr; 36(4): 713-720. 
[11] Ren XY, Shi D, Ding J, et al (2019). Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study (in English). Lipids Health Dis Feb 11; 18(1): 47.
[12] Zhao S, Zhang S, Zhao H, et al (2021). Coix lacryma-jobi Seed Oil Reduces Fat Accumulation in Nonalcoholic Fatty Liver Disease by Inhibiting the Activation of the p-AMPK/SePP1/apoER2 Pathway (in English). Sci Rep Dec 3; 10(1): 21117.
[13] Lee JH, Kim D, Kim HJ, et al (2010). Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease (in English). Dig Liver Dis Jul; 42(7): 503-508.
[14] Goyal O, Nohria S, Goyal P, et al (2020). Liraglutide in patients with non-alcoholic fatty liver disease: a prospective, observational, real world study (in English). Diabetes Metab Syndr Nov-Dec; 14(6): 2069-2074. 
[15] Goyal O, Nohria S, Goyal P, et al (2020). Saroglitazar Improves Liver Function and Lipid Profile in Patients with Non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia: A Real World Study (in English). J Clin Med Dec 3; 9(12): 3897.
[16] Reeder SB, Cruite I, Hamilton G, Sirlin CB (2011). Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy (in English). J Magn Reson Imaging Oct; 34(4): 729-749." I hope this revision meets your requirements and expectations.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4663
Visits: 203906

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.